RenovoRx, Inc.
RNXTNASDAQHealthcare● Active
$0.90
+$0.02(+1.91%)
Market Cap$33595562
P/E Ratio—
52W High$1.45
52W Low$0.701
RenovoRx, Inc. (RNXT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RNXT · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.12M | $0.04M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.33M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.80M | $0.04M | $0.00M | $0.00M | $0.00M |
| Gross Margin %(computed) | 70.88% | 100.00% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $6.27M | $6.03M | $5.67M | $4.30M | $3.04M |
| G&A Expenses | $7.04M | $4.99M | $5.73M | $5.65M | $2.63M |
| Total Operating Expenses | $13.31M | $11.01M | $11.40M | $9.95M | $5.67M |
| Operating Income | ($12.51M) | ($10.97M) | ($11.40M) | ($9.95M) | ($5.67M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.43M | $0.38M | $0.00M | $0.06M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.11M | $0.06M | $0.83M |
| Income Before Tax | ($11.17M) | ($8.81M) | ($10.23M) | ($9.89M) | ($6.32M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($11.17M) | ($8.81M) | ($10.23M) | ($9.89M) | ($6.32M) |
| Net Margin %(computed) | -994.48% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.32 | $-0.37 | $-0.50 | $-0.54 | $-0.40 |
| Wtd Avg Shares | 35.33M | 23.61M | 20.58M | 18.10M | 17.87M |
| EBITDA | ($12.51M) | ($10.97M) | ($11.39M) | ($9.94M) | ($5.48M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more RenovoRx, Inc. data
About RenovoRx, Inc. (RNXT) Income Statement
RenovoRx, Inc. (RNXT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RNXT reported revenue of $0.00B, gross profit of $0.00B (gross margin 70.88%), and net income of ($0.01B) — a net profit margin of -994.48%.
Frequently asked questions
RNXT · 4 questionsRenovoRx, Inc. (RNXT) reported revenue of $0.00B for 2025, up 2511.6% year-over-year.
RNXT revenueRNXT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09